<table>
<thead>
<tr>
<th>Clinical Trial</th>
<th>Location(s)</th>
<th>Current Status</th>
<th># of Patients</th>
<th>Taking sirolimus allowed?</th>
<th>Travel funds available?</th>
<th>Study Coordinator(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Observational &amp; Registry Studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| NIH | Bethesda, MD | Ongoing | NA | NA | Yes | Tania Machado, tania.machado@nih.gov  
Sara Hauff, sara.hauff@nih.gov  
(301)-496-3632 (o)  
(301)-648-5674 (c) |
| NDRI | Any | Ongoing | NA | NA | NA | Anne McKenna, amckenna@thelamfoundation.org  
(513) 777-6889 |
| MIDAS | Palo Alto, CA, Denver, CO, Jacksonville, FL, Atlanta, GA, Chicago, IL, Boston, MA, Ann Arbor, MI, Rochester, MN, St. Louis, MO, Rochester, NY, Cincinnati, OH, Cleveland, OH, Portland, OR, Philadelphia, PA, Charleston, SC, Nashville, TN, Dallas, TX, Houston, TX; Salt Lake City, UT, Seattle, WA | Enrolling through 04/2020 | 300 | YES | NO | All Sites: Susan McMahan, susan.mcmahan@uc.edu  
(513) 558-4376 (o) |
| **Interventional Studies** | | | | | | |
| COLA | Boston, MA & Bethesda, MD | Enrolling through 06/2018 | 12 | NO | YES | Boston, MA: Shefali Bagwe, sbagwe@bwh.harvard.edu  
(857) 307-0784 (o)  
Bethesda, MD: Tania Machado, tania.machado@nih.gov  
(301)-496-3632 (o)  
(301)-648-5674 (c) |
| LAMP-1 | Charleston, SC & New York, NY | Enrolling through 03/2018 | 20 | YES | YES (minimal, SC only) | Charleston, SC: Kimberly Brown, brownkl@musc.edu  
(843)-792-6474 (o)  
New York, NY: Laura Fonseca, lf2560@cumc.columbia.edu  
(212)-305-3745 (o) |
| MILED | Palo Alto, CA, Denver, CO, Atlanta, GA, Chicago, IL, Boston, MA, St. Louis, MO, Cincinnati, OH, Cleveland, OH, Philadelphia, PA, Nashville, TN, Seattle, WA | Enrolling through 06/2020 | 60 | NO | YES | All Sites: Sue McMahan, susan.mcmahan@uc.edu  
(513) 558-4376 (o) |
| SLAM-2 | Houston, TX, Palo Alto, CA, Chicago, IL, Boston, MA, Cincinnati, OH, Bethesda, MD | Enrolling through 07/2018 | 22 | NO | YES | All sites: Melissa Brock, mbrock@bcm.edu  
(713) 873-8772 (o) |
The purpose of this document is to summarize all currently enrolling clinical research trials and studies for LAM patients. For more detailed information about all ongoing, currently enrolling, and upcoming clinical research please visit TheLAMFoundation.org and review the Current Clinical Trials and Studies page.

**Ongoing Trials and Studies**
These trials include observational and registry studies.

- **National Institutes of Health (NIH)** - Study of the Disease Process of LAM  
  Principal Investigator: Joel Moss, MD, PhD

- **National Disease Research Interchange (NDRI)** – Tissue Donation

- **MIDAS** - Multi-Center International Durability and Safety of Sirolimus in LAM  
  Principal Investigator: Francis X. McCormack, MD

**Interventional Trials and Studies**
These trials require patients to take an investigational research drug or placebo pill.

- **A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC (COLA)**  
  Principal Investigator: David J. Kwiatkowski, MD, PhD

- **LAM Pilot Study with Imatinib Mesylate (LAMP-1)**  
  Principal Investigator: Jeanine D’Armiento, MD, PhD & Charlie Strange, MD

- **Multicenter Interventional LAM Early Disease (MILED)**  
  Principal Investigator: Francis X. McCormack, MD

- **Safety and Efficacy of Saracatinib in Subjects with LAM (SLAM-2)**  
  Principal Investigator: Tony Eissa, MD